Les publications

Breast cancer (BC) is one of the most common causes of cancer in the world and the second leading cause of cancer deaths among women. Mortality is associated mainly with the development of metastases. Identification of the mechanisms involved in metastasis formation is, therefore, a major public health issue.

n situ chemical reduction (ISCR) has been identified as a possible way for the remediation of soils contaminated by chlordecone (CLD). Evidences provided by the literature indicate an association between the development of prostate cancer and CLD exposure (Multigner et al. 2010).

Triple-negative breast cancer (TNBC) heterogeneity represents one of the main obstacles to precision medicine for this disease. Recent concordant transcriptomics studies have shown that TNBC could be divided into at least three subtypes with potential therapeutic implications.

The open-label, randomised Phase 2 AVATAXHER study (NCT01142778) demonstrated that early PET assessment identified HER2-positive breast cancer patients who responded poorly to neoadjuvant docetaxel plus trastuzumab.

In the present study, we investigated various biochemical, clinical, and histological factors associated with bone metastases in a large cohort of pre- and postmenopausal women with breast cancer. Two hundred and sixty-one consecutive women with breast cancer were included in this study.

Affitins are a novel class of small 7 kDa artificial proteins which can be used as antibody substitutes in therapeutic, diagnostic and biotechnological applications. One challenge for this type of protein agent is their behaviour in the context of oral administration.

In standard radiomics studies the features extracted from clinical images are mostly quantified with simple statistics such as the average or variance per Region of Interest (ROI). Such approaches may smooth out any intra-region heterogeneity and thus hide some tumor aggressiveness that may hamper predictions.

Les modalités de surveillance active (SA) d’un adénocarcinome prostatique (CaP) de faible risque intègrent dorénavant les données de l’IRM pour le calcul de la densité du PSA (PSAd) et la réalisation de biopsies ciblées. Le but de cette étude était d’évaluer la proportion de patients pouvant bénéficier d’une SA en fonction de critères pré-biopsiques comme le résultat de l’IRM et la densité du PSA.

Plusieurs modèles existent pour prédire le risque d’envahissement ganglionnaire pelvien mais aussi le risque de récidive biologique après prostatectomie dans le cancer de prostate localisé. Ces scores ont été validés dans des populations en majorité caucasienne. Peu de données sont disponibles pour les populations d’ascendance africaine.